Abstract
The aim of this study was to evaluate the effect of linker on tumor targeting and biodistribution of (67)Cu-NOTA-PEG(2)Nle-CycMSH(hex) {(67)Cu-1,4,7-triazacyclononane-1,4,7-triyl-triacetic acid-polyethylene glycol-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-CONH(2)} and (67)Cu-NOTA-GGNle-CycMSH(hex) {(67)Cu-NOTA-GlyGlyNle-CycMSH(hex)} on melanoma-bearing mice. NOTA-PEG(2)Nle-CycMSH(hex) and NOTA-GGNle-CycMSH(hex) were synthesized and purified by HPLC. The biodistribution of (67)Cu-NOTA-PEG(2)Nle-CycMSH(hex) and (67)Cu-NOTA-GGNle-CycMSH(hex) was determined in B16/F10 melanoma-bearing C57 mice. The melanoma imaging property of (67)Cu-NOTA-PEG(2)Nle-CycMSH(hex) was further examined in B16/F10 melanoma-bearing C57 mice. (67)Cu-NOTA-PEG(2)Nle-CycMSH(hex) exhibited higher tumor uptake than (67)Cu-NOTA-GGNle-CycMSH(hex) at 2, 4, and 24 h post-injection. The tumor uptake of (67)Cu-NOTA-PEG(2)Nle-CycMSH(hex) was 27.97 ± 1.98, 24.10 ± 1.83, and 9.13 ± 1.66% ID/g at 2, 4, and 24 h post-injection, respectively. Normal organ uptake of (67)Cu-NOTA-PEG(2)Nle-CycMSH(hex) was lower than 2.6% ID/g at 4 h post-injection, except for kidney uptake. The renal uptake of (67)Cu-NOTA-PEG(2)Nle-CycMSH(hex) was 6.43 ± 1.31, 2.60 ± 0.79, and 0.90 ± 0.18% ID/g at 2, 4, and 24 h post-injection, respectively. (67)Cu-NOTA-PEG(2)Nle-CycMSH(hex) showed high tumor to normal organ uptake ratios after 2 h post-injection. The B16/F10 melanoma lesions could be clearly visualized by single photon emission computed tomography (SPECT) using (67)Cu-NOTA-PEG(2)Nle-CycMSH(hex) as an imaging probe at 4 h post-injection. The favorable tumor targeting and biodistribution properties of (67)Cu-NOTA-PEG(2)Nle-CycMSH(hex) underscored its potential as an MC1R-targeted therapeutic peptide for melanoma treatment.